Journal Reviews
Ocular adnexal mantle cell lymphoma
In this study the authors compare primary ocular adnexal (OA) mantle cell lymphoma (MCL) with initially systemic MCL occurring over a 30-year period. MCL is a rare form of lymphoma accounting for 5-11% of OA lymphomas and therefore knowledge of...
Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma single institutional experience
Ocular adnexal lymphomas constitute 2% of all non-Hodgkin’s disease and 5-15% of all extranodal lymphomas and are usually localised, low-grade and of B-cell origin. This opens them up to potential treatment with a systemic monoclonal antibody-based drug (rituximab) directed at...
